The evidence leans constructive5 supporting, 0 against, 1 worth knowing
Supporting
trading 30% above its 200-day average
up 36% over twelve months
3 independent kinds of evidence agree today, which is uncommon
revenue grew 76% year on year in the quarter ending 2026-06-30
net margin has widened from -3.0% to 1.1% across four quarters
Against
nothing the data supports either way
Worth knowing
the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
What would change this read: a close below 769, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working1
Revenue +75.9% year on year, Rs 173 cr to Rs 304 cr.
+75.9%Rs 173 crRs 304 cr
Needs watching3
Net profit -78.4% year on year, Rs 15 cr to Rs 3 cr.
-78.4%Rs 15 crRs 3 cr
Profit grew slower than revenue, -78.4% against +75.9%.
-78.4%+75.9%
Net margin moved from 8.6% to 1.1%.
8.6%1.1%
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
3 of 47 matched on 2026-08-21
ORCHPHARMA matches 3 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
ORCHPHARMA trades at 304× trailing earnings, above its median of 78× over this window — 290% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Fundraise filings were typically +0.59pt vs the market over the next 5 sessions (n=266)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 76% against the same quarter a year earlier
revenue rose in 4 of the last 4 quarters
Going against it
profit dropped 78% year on year
net margin narrowed from 10.0% to 1.1%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
304
3
3
0.54
1.1%
Q4 FY26
2026-03-31 · consolidated
238
23
24
4.69
10.0%
Q3 FY26
2025-12-31 · consolidated
207
-12
-13
—
-6.1%
Q2 FY26
2025-09-30 · consolidated
194
-3
-6
—
-3.0%
Q1 FY26
2025-06-30 · consolidated
173
14
15
2.94
8.6%
Q4 FY25
2025-03-31 · consolidated
237
19
22
4.40
9.4%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-0.1%
Versus 200-day average+30.2%
Below 52-week high-9.0%
Above 52-week low+107.7%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)52.0
Higher closes in last 53 of 5
Six-month return+59.68%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.